Last updated: June 4, 2026
Lidocaine hydrochloride and epinephrine combination products are supplied through (1) upstream API makers for lidocaine hydrochloride and (2) epinephrine suppliers, with finished-goods procurement commonly handled by sterile injectables and specialty injectables manufacturers under OEM/contract manufacturing arrangements. No supplier roster can be produced from the information provided.
What companies supply lidocaine hydrochloride API for injectable products?
Direct suppliers for lidocaine hydrochloride API depend on the target market (US FDA vs EU vs ROW), dosage form (injection vs dental cartridges vs topical anesthetic), and whether procurement is for USP/EP-grade or injection-ready material.
Which regions supply lidocaine hydrochloride API
Finished injectables in the US often rely on API sourcing that is regionally diversified:
- North America: for regulated secondary sourcing and supply assurance
- Europe: for CEP-equivalent expectations and quality alignment
- India and China: high-volume API production is common for anesthetics, with qualification typically required for DMF access, CEP/CoA compliance, and sterile drug component traceability
What to check before qualifying lidocaine hydrochloride API sources
For injectable use, buyers typically require documentation aligned to injectable drug substance expectations:
- DMF or ASMF availability and letter-of-access scope
- impurity profile and acceptable limits for injectable-grade specifications
- nitrosamine risk controls where applicable to broader anesthetic supply chains
- change control history and batch reproducibility evidence
What companies supply epinephrine API for lidocaine with epinephrine formulations?
Epinephrine API supply tends to be narrower than lidocaine due to stability, assay, and sensitive impurity controls required for injectable use.
How epinephrine supply affects formulation readiness
Epinephrine is oxidation- and light-sensitive. Source qualification typically includes:
- validated packaging and light-protection requirements
- defined antioxidant/stabilizer systems if used in the API or carried through manufacturing
- shelf-life and retest intervals aligned to sterile injectable timelines
What buyers request from epinephrine API suppliers
- stability-indicating assay methods
- forced degradation characterization and impurity mapping
- delivery of CoA with relevant acceptance criteria and traceability
Who supplies lidocaine hydrochloride and epinephrine finished injectables in the US?
Finished injectables are supplied by manufacturers selling through US distribution channels, including branded and generic sterile injectables.
How procurement usually works for finished products
Common procurement paths include:
- direct purchase from the marketing authorization holder (MAH)
- sourcing through wholesalers with batch traceability support
- OEM contract manufacturing where the buyer controls labeling and package configuration
Key qualification checks for finished lidocaine with epinephrine injectables
- inspection history for sterile manufacturing
- hold time and sterilization validation approach (where relevant to manufacturing design)
- container closure system and packaging integrity studies
- lot-level deliverable specs and validated sterility assurance parameters
What patent or regulatory constraints affect supply of lidocaine with epinephrine?
Supply availability is often driven less by patent exclusivity and more by regulatory standing of sterile products and ingredient specs.
How FDA listings typically drive supply
- Orange Book status controls for “drug products” that have listed patents in the US
- generic readiness depends on ANDA status and formulation sameness requirements
What matters in regulatory submissions
- equivalence of concentration, active ingredient forms, and functional excipients
- microbiological and sterility control strategy for injectables
- antimicrobial effectiveness testing approach when relevant to non-sterile or multi-dose systems (less common for sterile injectables)
Which suppliers provide contract manufacturing for sterile anesthetic injectables?
Contract manufacturing for sterile injectables is typically handled by CDMOs with sterile fill-finish capacity and established GMP systems.
What CDMOs need to support lidocaine with epinephrine work
- aseptic fill-finish capability (or terminal sterilization capability if applicable to the exact formulation)
- validated compatibility studies for epinephrine stability with the container closure system
- controlled handling procedures for light/oxygen exposure
How buyers screen sterile CDMOs
- audit readiness and quality agreement templates
- deviation and CAPA cadence for sterile operations
- batch record traceability and change-control discipline for small-molecule injectables
How do you compare supplier options for lidocaine/epinephrine products?
Comparisons should focus on supply reliability and qualification velocity rather than catalog availability alone.
Comparison matrix for supplier selection
| Supplier Type |
What they provide |
Qualification bottlenecks |
Typical procurement lead time driver |
| Lidocaine API supplier |
Lidocaine hydrochloride API |
impurity profile and DMF access scope |
DMF/CoA alignment and change control review |
| Epinephrine API supplier |
Epinephrine API |
oxidation control, stability proof |
retest window confirmation and stability data |
| Finished product manufacturer |
US-marketed sterile injectables |
sterile lot consistency and labeling claims |
sterility assurance and CMC package review |
| CDMO/OEM |
Sterile fill-finish and labeling support |
aseptic validation and compatibility |
onboarding audit and process transfer timeline |
What generic entry risks exist for lidocaine with epinephrine?
Generic entry risk is usually tied to:
- feasibility of bioequivalence for sterile injectables (often formulation and process equivalence)
- CMC package completeness (particle/clarity, pH, antioxidant profile)
- sterile manufacturing reliability
Key Takeaways
- Lidocaine hydrochloride and epinephrine combination supply comes from API upstream plus sterile injectable finished-goods manufacturing, often via CDMO/OEM routes.
- Supplier selection for injectable use hinges on DMF/ASMF access, impurity/stability controls (especially epinephrine oxidation), and sterile manufacturing quality systems.
- A specific supplier list cannot be generated from the provided input.
FAQs
- What grade specifications are typically required for lidocaine hydrochloride API in injectable products?
- How do epinephrine stability requirements change container closure and handling during manufacturing?
- What documentation is commonly requested to qualify a lidocaine with epinephrine finished injectable supplier for US distribution?
- Do suppliers differ materially in impurity profiles for lidocaine hydrochloride, and how is this assessed?
- What sterile fill-finish process choices (aseptic vs terminal sterilization) are most common for anesthetic epinephrine-containing injectables?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. FDA. Drug Master Files (DMF). https://www.fda.gov/drugs/datasources-drugs/drug-master-files-dmfs
- European Medicines Agency. Assessment of bioequivalence and product sameness concepts. https://www.ema.europa.eu/
